Phase 3 Study of YM060 in Patients With Diarrhea-predominant Irritable Bowel Syndrome (d-IBS)

Astellas Pharma Inc

Overview

This study will examine the efficacy, safety and tolerability of oral dose of YM060, 5-HT3 receptor antagonist, in patients with d-IBS.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Conditions

Irritable Bowel Syndrome

Interventions

YM060DRUG

Eligibility

Sex: ALLMin age: 20 YearsMax age: 64 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients satisfying the Rome II Diagnostic Criteria. * Patients in whom no organic changes were observed in large intestine. Exclusion Criteria: * Patients have diseases which interfere with evaluation of the efficacy and safety in this study. * Patients are receiving and/or have received prior to the enrollment the treatment which interfere with evaluation of the efficacy and safety in this study.

Locations (4)

Unnamed facility

Chubu Region, Japan

Unnamed facility

Kanto Region, Japan

Unnamed facility

Shikoku Region, Japan

Unnamed facility

Tohoku Region, Japan

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.